These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1353607)

  • 1. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
    N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
    N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
    N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
    Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
    Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
    Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
    Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD
    Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
    Hamilton JD; Hartigan PM; Simberkoff MS; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM
    N Engl J Med; 1992 Feb; 326(7):437-43. PubMed ID: 1346337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
    N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
    Katzenstein DA; Hammer SM; Hughes MD; Gundacker H; Jackson JB; Fiscus S; Rasheed S; Elbeik T; Reichman R; Japour A; Merigan TC; Hirsch MS
    N Engl J Med; 1996 Oct; 335(15):1091-8. PubMed ID: 8813039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
    J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.